Empliciti (elotuzumab) / AbbVie, BMS  >>  Phase 2
Welcome,         Profile    Billing    Logout  

42 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Empliciti (elotuzumab) / AbbVie, BMS
NCT01632150 / 2011-005121-49: Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Checkmark elotuzumab in combination with lenalidimide and dexamethasone
Jun 2013 - Jun 2013: elotuzumab in combination with lenalidimide and dexamethasone
Completed
2a
51
Europe
Elotuzumab, BMS-901608, HuLuc63, Thalidomide, Thalomid®, Dexamethasone, Decadron®, Dexamethasone Intensol®, Dexpak®, Taperpak®, Cyclophosphamide, Cytoxan, Endoxan, Neosar
Bristol-Myers Squibb, AbbVie
Relapsed and/or Refractory Multiple Myeloma
10/13
03/16
NCT01478048 / 2011-002695-16: Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Checkmark ASH 2015
Nov 2015 - Nov 2015: ASH 2015
Completed
2
185
US, Canada, Europe
Elotuzumab, BMS-901608, Bortezomib, Velcade®, Dexamethasone, Decadron®, Intensol®, Dexpak®, Taperpak®
Bristol-Myers Squibb, AbbVie
Multiple Myeloma
05/14
04/17
NCT01441973: Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Checkmark EHA 2016
May 2016 - May 2016: EHA 2016
Completed
2
41
US
Elotuzumab (BMS-901608; HuLuc63)
Bristol-Myers Squibb, AbbVie
Smoldering Multiple Myeloma
05/14
01/17
NCT02159365: Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

Completed
2
84
US
Elotuzumab, BMS-901608, Lenalidomide, Revlimid, Dexamethasone
Bristol-Myers Squibb
Multiple Myeloma
06/16
07/18
NCT02272803: Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

Completed
2
82
Japan
Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608)
Bristol-Myers Squibb, AbbVie
Multiple Myeloma
02/17
07/21
ELOQUENT-3, NCT02654132 / 2014-003282-19: An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma

Checkmark Approved in combination with pomalidomide and low-dose dexamethasone (EPd) for 3L multiple myeloma
Aug 2019 - Aug 2019: Approved in combination with pomalidomide and low-dose dexamethasone (EPd) for 3L multiple myeloma
Checkmark CHMP recommends positive opinion for the 2L treatment of multiple myeloma patients in combination with pomalidomide and dexamethasone
Jul 2019 - Jul 2019: CHMP recommends positive opinion for the 2L treatment of multiple myeloma patients in combination with pomalidomide and dexamethasone
Checkmark From ELOQUENT-3 trial in combination with pomalidomide and dexamethasone at EHA 2019
More
Completed
2
117
Europe, Canada, Japan, US, RoW
Elotuzumab, Pomalidomide, Pomalyst, Dexamethasone, Decadron, Dexamethasone, Intensol, Dexpak, Taperpak
Bristol-Myers Squibb, Celgene, AbbVie
Multiple Myeloma
01/18
10/21
NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Completed
2
51
US
Elotuzumab, HuLuc63, Lenalidomide, REVLIMID, Dexamethasone, Decadron
Dana-Farber Cancer Institute, Bristol-Myers Squibb, Celgene, Blood Cancer Research Partnership, Multiple Myeloma Research Consortium, The Leukemia and Lymphoma Society
Smoldering Myeloma, Smoldering Multiple Myeloma
12/18
01/22
IFM2016-03, NCT03393273 / 2017-001446-10: Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft

Withdrawn
2
0
Europe
Elotuzumab, Empliciti®
Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
01/19
01/19
NCT03168100: 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

Withdrawn
2
0
US
Elotuzumab, Empliciti, Lenalidomide, Revlimid, Dexamethasone, Decadron, Bortezomib, Velcade
University of Arkansas
Multiple Myeloma
01/19
01/19
NCT02612779: A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

Completed
2
74
US
Elotuzumab, Pomalidomide, Dexamethasone, Nivolumab
Bristol-Myers Squibb
Multiple Myeloma
07/19
06/20
NCT03104270: Combination Study for High Risk Multiple Myeloma Patients

Terminated
2
13
US
Elotuzumab, BMS-901608, Pomalidomide, CC-4047, Pomalyst, Carfilzomib, Kyprolis, Dexamethasone, Steroid
Oncotherapeutics
Multiple Myeloma
10/19
01/20
NCT03003728: 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

Withdrawn
2
0
US
Elotuzumab, Empliciti, Melphalan, Autologous Stem Cell Transplant (ASCT), Expanded Natural Killer (ENK) Cells, ALT-803, IL-15 superagonist
University of Arkansas, Bristol-Myers Squibb, Altor BioScience
Multiple Myeloma
07/20
07/20
NCT03411031: Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

Terminated
2
18
US
Elotuzumab, Empliciti™, BMS-901608, HuLuc63, Lenalidomide, REVLIMID®, thalidomide analogue, Dexamethasone, Decadron
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Multiple Myeloma
02/21
11/21
Elo-KRd, NCT03361306: LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

Completed
2
15
US
Elotuzumab, Empliciti
Wake Forest University Health Sciences, Bristol-Myers Squibb, Atrium Health Levine Cancer Institute
Multiple Myeloma
06/21
02/25
NCT02843074: Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

Completed
2
53
US
elotuzumab, Empliciti, Lenalidomide, Revlimid, Dexamethasone, Decadron, autologous stem cell transplantation, ASCT
SCRI Development Innovations, LLC, Bristol-Myers Squibb
Multiple Myeloma
07/21
10/21
NCT02375555: Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

Completed
2
40
US
Lenalidomide, Revlimid®, Elotuzumab, HuLuc63, Bortezomib, Velcade, Dexamethasone, Baycadron Elixer, Decadron, Stem Cell Mobilization
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Multiple Myeloma
12/21
01/24
NCT03227432: An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

Withdrawn
2
0
US
Dexamethasone, Maxidex, Pomalidomide, Pomalyst, Elotuzumab, Empliciti, Nivolumab, Opdivo
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Multiple Myeloma
12/21
12/24
ESdRRMM, NCT05170789: Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma

Withdrawn
2
0
NA
Elotuzumab, Selinexor, and Dexamethasone (ESd)
Tulane University School of Medicine, Karyopharm Therapeutics Inc
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
04/22
04/22
NCT02718833: A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Active, not recruiting
2
52
US
Elotuzumab, Empliciti, Pomalidomide, Pomalyst, Bortezomib, Velcade, Dexamethasone, Decadron
Massachusetts General Hospital, Celgene, Bristol-Myers Squibb, Multiple Myeloma Research Consortium
Multiple Myeloma
12/25
06/26
CA204-225, NCT03030261: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Active, not recruiting
2
25
Canada, US
Elotuzumab, Empliciti, Pomalidomide, Pomalyst, Dexamethasone, Decadron
Washington University School of Medicine, Bristol-Myers Squibb, Celgene
Multiple Myeloma in Relapse
09/22
09/27
NCT03000634: 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy

Withdrawn
2
0
NA
Elotuzumab, Elo, Bortezomib, Velcade, Lenalidomide, Revlimid, Dexamethasone, Decadron
University of Arkansas
Multiple Myeloma
04/17
04/17
NCT03155100 / 2016-001178-13: Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines

Completed
2
15
Europe
Carfilzomib for Inj 60 milligram (MG), Proteasome inhibitor, Elotuzumab 400 MG, Monoclonal antibody, Dexamethasone, Steroid
Raija Silvennoinen, Amgen, Bristol-Myers Squibb, Hospital District of Helsinki and Uusimaa
Multiple Myeloma in Relapse
08/23
08/23
Immuno-POWER, NCT04584307: Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant

Withdrawn
2
0
NA
Elotuzumab, Pomalidomide
Natalie Callendar, Bristol-Myers Squibb
Multiple Myeloma
12/23
12/24
NCT03252600: Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Active, not recruiting
2
53
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Pharmacological Study
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI), Bristol-Myers Squibb, Multiple Myeloma Research Consortium
Recurrent Primary Amyloidosis
12/23
12/23
CA204-185, NCT02719613 / 2016-000037-51: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Active, not recruiting
2
67
Europe, Canada, Japan, US, RoW
Elotuzumab, BMS-901608, HuLuc63, Empliciti, Dexamethasone, Lenalidomide, Revlimid®, Bortezomib, Velcade®, Pomalidomide, Pomalyst ®, Nivolumab, Opdivo ®
Bristol-Myers Squibb, AbbVie
Multiple Myeloma
11/25
11/25
IMPEDE, NCT04835129: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma

Recruiting
2
53
US
Isatuximab (for run-in portion), Sarclisa, SAR-650984, isatuximab-irfc, Isatuximab (for expansion), Pomalidomide, Pomalyst, Imnovid, Elotuzumab, Empliciti, HuLuc63, Dexamethasone, Baycadron, Decadron, DexPak, TaperDex, Zema-Pak, ZoDex, Zonacort
Medical College of Wisconsin
Multiple Myeloma
01/26
01/27
NCT02420860: Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting
2
113
US
Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
04/27
04/27
RV-MM-PI-0691, NCT01729091: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed
2
72
US
Autologous Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Cell Transplantation, autologous stem cell transplantation, Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine nitrogen mustard, Sarcoclorin, Sarkolysin, WR-19813, Natural Killer Cell Therapy, Umbilical Cord Blood-Derived Lymphocyte Therapy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Plasma Cell Leukemia, Plasma Cell Myeloma
06/24
06/24
NCT03713294: Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

Completed
2
37
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Pomalidomide, 4-Aminothalidomide, Actimid, CC-4047, Imnovid, Pomalyst
Mayo Clinic, National Cancer Institute (NCI)
Refractory Plasma Cell Myeloma
02/24
11/24
NCT04517851: Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Active, not recruiting
2
15
US
Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Questionnaire Administration
M.D. Anderson Cancer Center
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
12/27
12/27
Elo-KRd, NCT02969837: Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

Completed
2
46
US
Elotuzumab, Empliciti, Carfilzomib, Kryprolis, Lenalidomide, Revlimid, Dexamethasone
University of Chicago, Bristol-Myers Squibb, Amgen, Multiple Myeloma Research Foundation
Multiple Myeloma
10/21
12/25
NCT04918147: Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Terminated
2
8
US
elotuzumab, BMS-901608, Empliciti®, placebo for elotuzumab, normal saline, methylprednisolone, Solu-Medrol®, diphenhydramine, Benadryl®, acetaminophen, Tylenol®, famotidine, H2 blocker, prednisone, corticosteroid
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Bristol-Myers Squibb, Rho Federal Systems Division, Inc.
IgG4 Related Disease, IgG4-RD
01/24
01/24
NCT00742560 / 2007-006677-83: A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Checkmark Multiple myeloma
Dec 2015 - Dec 2015: Multiple myeloma
Checkmark P2 data EHA 2012
May 2012 - May 2012: P2 data EHA 2012
Checkmark P1/2 data at ASH
More
Completed
1b/2
101
NA
elotuzumab, HuLuc63, lenalidomide, dexamethasone oral, dexamethasone injection
AbbVie (prior sponsor, Abbott), Bristol-Myers Squibb
Hematologic Cancer
10/16
10/16
NCT00726869: A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

Checkmark Data
Jun 2011 - Jun 2011: Data
Terminated
1/2
28
US
Elotuzumab (HuLuc63), Elotuzumab
Abbott, Bristol-Myers Squibb
Multiple Myeloma
03/12
03/12
SWOG-1211, NCT01668719: S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

Active, not recruiting
1/2
142
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Elotuzumab, BMS-901608, HuLuc63, PDL-063, PDL063, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid
SWOG Cancer Research Network, National Cancer Institute (NCI)
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
02/20
12/25
NCT05002816: Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

Recruiting
1/2
24
US
Elotuzumab, Belantamab mafodotin
Yale University, GlaxoSmithKline
Multiple Myeloma
01/26
12/26
NCT04065425: Phase I/II Assessment of Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Not yet recruiting
1/2
104
NA
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3 Monoclonal Antibody BMS-986016, pomalidomide, dexamethasone, BMS-986016, Anti LAG-3, Relatlimab, Anti-TIGIT Monoclonal Antibody BMS-986207, pomalidomide, dexamethasone, BMS-986207, Anti TIGIT
Multiple Myeloma Research Consortium, Bristol-Myers Squibb
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
10/23
10/23
CC-92480-MM-002, NCT03989414 / 2018-004767-31: A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Active, not recruiting
1/2
424
Europe, Canada, US, RoW
CC-92480, BMS-986348, mezigdomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib, Elotuzumab, Isatuximab
Celgene
Multiple Myeloma
11/26
11/26
NCT04150965: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Terminated
1/2
14
US
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3, BMS-986016, Anti LAG-3, Relatlimab, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-LAG-3, Pomalidomide, Dexamethasone, Anti-TIGIT, BMS-986207, Anti-TIGIT + Pomalidimide + Dexamethasone
Multiple Myeloma Research Consortium, Bristol-Myers Squibb, Emory University, Washington University School of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Wake Forest University Health Sciences, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, University of Texas, Hackensack Meridian Health, University of Michigan
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
08/24
08/24
NCT06518551: Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Recruiting
1/2
49
US
Elotuzumab, BMS-901608, Iberdomide, CC-220, Iberdomide hydrochloride, C25H28N3O5Cl, BMS-986382, Dexamethasone, Decadron, 9- fluoro11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione
Omar Nadeem, MD, Celgene, Bristol-Myers Squibb
Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
12/29
12/34
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Hourglass Feb 2024 - Dec 2024 : Results from STOMP trial for RRMM and NDMM
Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
More
Recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
NCT06785415: Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Recruiting
1/2
37
US
Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Bone Scan, Bone Scintigraphy, Chest Radiography, Chest X-ray, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Daratumumab, Daratumumab Biosimilar HLX15, Daratumumab-fihj, Darzalex, HLX15, HuMax-CD38, JNJ 54767414, JNJ-54767414, JNJ54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Elotuzumab, BMS 901608, BMS-901608, BMS901608, Empliciti, HuLuc-63, HuLuc63, PDL 063, PDL-063, PDL063, Iberdomide, CC 220, CC-220, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Mayo Clinic
Recurrent Multiple Myeloma
04/31
04/31

Download Options